$CNTX News

Context Therapeutics Q1 EPS $(0.09) Beats $(0.12) Estimate

Context Therapeutics Receives FDA's Fast Track Designation For CTIM-76 To Treat Platinum-Resistant Ovarian Cancer

Guggenheim Reiterates Buy on Context Therapeutics, Maintains $5 Price Target

Piper Sandler Maintains Overweight on Context Therapeutics, Raises Price Target to $7

Context Therapeutics Q4 EPS $(0.14) Misses $(0.10) Estimate

Context Therapeutics to Participate in Upcoming Investor Conferences

Here's Why We're Not Too Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Situation

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jones Trading Initiates Coverage On Context Therapeutics with Buy Rating, Announces Price Target of $7

BioAtla Inc (BCAB) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Promising Trial ...

BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting

Context Therapeutics Showcases CT-95 And CT-202 At 2025 SITC; CT-95 Advancing In Phase 1 With Favorable Safety, Initial Data Mid-2026; CT-202 Targeting First-In-Human In Q2 2026

Context Therapeutics Showcases CT-95 And CT-202 At 2025 SITC; CT-95 Advancing In Phase 1 With Favorable Safety, Initial Data Mid-2026; CT-202 Targeting First-In-Human In Q2 2026

D. Boral Capital Maintains Buy on Context Therapeutics, Maintains $9 Price Target

HC Wainwright & Co. Maintains Buy on Context Therapeutics, Raises Price Target to $5

Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results

Context Therapeutics Q3 EPS $(0.10) Misses $(0.09) Estimate

Context Therapeutics to Participate in Upcoming Investor Conferences

Context Therapeutics Amends Sales Agreement, May Offer & Sell From Time To Time Common Stock Of Up To $75M